TY - JOUR
T1 - Analysis of Fcγ receptor IIIa and IIa polymorphisms
T2 - Lack of correlation with outcome in trastuzumab-treated breast cancer patients
AU - Hurvitz, Sara A.
AU - Betting, David J.
AU - Stern, Howard M.
AU - Quinaux, Emmanuel
AU - Stinson, Jeremy
AU - Seshagiri, Somasekar
AU - Zhao, Ying
AU - Buyse, Marc
AU - Mackey, John
AU - Driga, Adrian
AU - Damaraju, Sambasivarao
AU - Sliwkowski, Mark X.
AU - Robert, Nicholas J.
AU - Valero, Vicente
AU - Crown, John
AU - Falkson, Carla
AU - Brufsky, Adam
AU - Pienkowski, Tadeusz
AU - Eiermann, Wolfgang
AU - Martin, Miguel
AU - Bee, Valerie
AU - Marathe, Omkar
AU - Slamon, Dennis J.
AU - Timmerman, John M.
PY - 2012/6/15
Y1 - 2012/6/15
N2 - Purpose: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcγ receptors (FcγR) on leukocytes may contribute to its antitumor effects. Single-nucleotide polymorphisms (SNP) in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131, respectively, and affect binding of antibodies to FcγR such that 158V/V and 131H/H bind with highest affinity. This study aimed to determine whether high-affinity SNPs are associated with disease-free survival (DFS) among patients with HER2-positive nonmetastatic breast cancer. Experimental Design: Genomic DNA was isolated from 1,286 patients enrolled in a trial of adjuvant trastuzumab-based chemotherapy. Genotyping was conducted using Sanger sequencing and Sequenom mass spectrometry. Results: Patient samples (N = 1,189) were successfully genotyped for FCGR3A and 1,218 for FCGR2A. Compared with the overall results of the BCIRG006 study, in the subset of patients genotyped in this analysis, a less robust improvement in DFS was observed for the trastuzumab arms than control arm (HR, 0.842; P = 0.1925). When stratified for prognostic features, the HR in favor of trastuzumab was consistent with that of the overall study (HR, 0.74; P = 0.036). No correlation between DFS and FCGR3A/2A genotypes was seen for trastuzumab-treated patients (158V/V vs. V/F vs. F/F, P = 0.98; 131H/H vs. H/R vs. R/R, P = 0.76; 158V/V and/or 131H/H vs. others, P = 0.67). Conclusion: This analysis evaluating the association between FCGR3A/2A genotypes and trastuzumab efficacy in HER2-positive breast cancer did not show a correlation between FCGR3A-V/F and FCGR2A-H/R SNPs and DFS in patients treated with trastuzumab.
AB - Purpose: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcγ receptors (FcγR) on leukocytes may contribute to its antitumor effects. Single-nucleotide polymorphisms (SNP) in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131, respectively, and affect binding of antibodies to FcγR such that 158V/V and 131H/H bind with highest affinity. This study aimed to determine whether high-affinity SNPs are associated with disease-free survival (DFS) among patients with HER2-positive nonmetastatic breast cancer. Experimental Design: Genomic DNA was isolated from 1,286 patients enrolled in a trial of adjuvant trastuzumab-based chemotherapy. Genotyping was conducted using Sanger sequencing and Sequenom mass spectrometry. Results: Patient samples (N = 1,189) were successfully genotyped for FCGR3A and 1,218 for FCGR2A. Compared with the overall results of the BCIRG006 study, in the subset of patients genotyped in this analysis, a less robust improvement in DFS was observed for the trastuzumab arms than control arm (HR, 0.842; P = 0.1925). When stratified for prognostic features, the HR in favor of trastuzumab was consistent with that of the overall study (HR, 0.74; P = 0.036). No correlation between DFS and FCGR3A/2A genotypes was seen for trastuzumab-treated patients (158V/V vs. V/F vs. F/F, P = 0.98; 131H/H vs. H/R vs. R/R, P = 0.76; 158V/V and/or 131H/H vs. others, P = 0.67). Conclusion: This analysis evaluating the association between FCGR3A/2A genotypes and trastuzumab efficacy in HER2-positive breast cancer did not show a correlation between FCGR3A-V/F and FCGR2A-H/R SNPs and DFS in patients treated with trastuzumab.
UR - http://www.scopus.com/inward/record.url?scp=84862522354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862522354&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-11-2294
DO - 10.1158/1078-0432.CCR-11-2294
M3 - Article
C2 - 22504044
AN - SCOPUS:84862522354
SN - 1078-0432
VL - 18
SP - 3478
EP - 3486
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -